Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > pre-BTD and BTD

<< Previous

Bullboard Posts

Next >>

Comment by N0taP00pon Nov 06, 2023 2:52pm

185 Views

Post# 35719949

RE:RE:pre-BTD and BTD

The Market Herald "article" clearly says pre-BTD submission in the next 6 months. And you're saying the email says by the end of the year. Probably 2023. One of them is right. Maybe they need to correct the article then?

skier59 wrote:

Theralase® expects to apply for pre-Breakthrough Therapy Designation (“BTD”) before year end.

This is what they stated in today's NR via emails. So hopefully they are referring to 2023.